
Lantern Pharma Receives FDA Clearance for Pediatric CNS Cancer Trial of STAR-001
Lantern Pharma has obtained FDA clearance for its Phase 1 pediatric clinical trial of STAR-001, targeting relapsed or refractory central nervous system malignancies through its AI-driven RADR platform, potentially addressing critical unmet needs in aggressive pediatric brain cancers.
Read full story





















